Independent directory Public ClinicalTrials.gov records United States
Clear filters
ClinicalTrials.gov public records Last synced Sep 1, 2026, 12:37 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–13 of 13 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Conditions
Respiratory Syncytial Virus (RSV)
Interventions
RSVpreF MDV, RSVpreF SDV
Biological
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 49 Years · Female only
Enrollment
453 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024
U.S. locations
6
States / cities
South Miami, Florida • Stockbridge, Georgia • Idaho Falls, Idaho + 3 more
Conditions
RSV Infection
Interventions
RSVpreF, Placebo
Biological
Lead sponsor
Pfizer
Industry
Eligibility
0 Years and older
Enrollment
550 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2028
U.S. locations
80
States / cities
Birmingham, Alabama • Mobile, Alabama • Los Angeles, California + 28 more
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Clinical Lot Consistency for RSVpreF in a Population of Healthy Adults 18 to ≤49 Years of Age

NCT05096208
Conditions
RSV
Interventions
RSVpreF (Group 1), RSVpreF (Group 2), RSVpreF (Group 3), Placebo
Biological
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 49 Years
Enrollment
1,028 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2022
U.S. locations
18
States / cities
Miami Lakes, Florida • Sunrise, Florida • Winter Park, Florida + 13 more
Conditions
Respiratory Tract Infection
Interventions
RSVpreF, Placebo
Biological
Lead sponsor
Pfizer
Industry
Eligibility
0 Years to 49 Years · Female only
Enrollment
14,727 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2023
U.S. locations
363
States / cities
Birmingham, Alabama • Cullman, Alabama • Mobile, Alabama + 137 more
Conditions
RESPIRATORY SYNCYTIAL VIRUS (RSV)
Interventions
RSVpreF, Placebo
Biological · Other
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
885 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
36
States / cities
Athens, Alabama • Birmingham, Alabama • Huntsville, Alabama + 28 more
Conditions
CAR-T Cell Therapy, RSV Immunization, Bone Marrow Transplant - Autologous or Allogeneic
Interventions
Respiratory Syncytial Virus Prefusion F Vaccine (RSVpreF)
Biological
Lead sponsor
The Cooper Health System
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
1
States / cities
Camden, New Jersey
Conditions
Respiratory Syncytial Virus (RSV)
Interventions
RESPIRATORY SYNCYTIAL VIRUS PREFUSION F SUBUNIT VACCINE, HZ/su VACCINE
Biological
Lead sponsor
Pfizer
Industry
Eligibility
50 Years and older
Enrollment
526 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025
U.S. locations
25
States / cities
Birmingham, Alabama • Huntsville, Alabama • Mobile, Alabama + 22 more
Conditions
Healthy Participants
Interventions
Combination [RSVpreF+BNTb162b2], Bivalent BNT162b2 (original/Omi BA.4/BA.5), RSVpreF, QIV, Normal Saline Placebo
Biological
Lead sponsor
Pfizer
Industry
Eligibility
65 Years and older
Enrollment
1,142 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2024
U.S. locations
37
States / cities
Dublin, California • Huntington Beach, California • Lake Forest, California + 26 more
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Immunogenicity of RSV Vaccines in Residents of Long-Term Care Facilities (LTCF)

NCT06077149
Conditions
Respiratory Syncytial Virus (RSV)
Interventions
RSV vaccine
Biological
Lead sponsor
University of Rochester
Other
Eligibility
60 Years and older
Enrollment
152 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2024
U.S. locations
1
States / cities
Rochester, New York
Conditions
RESPIRATORY SYNCYTIAL VIRUS (RSV)
Interventions
RSVpreF 120 µg, RSVpreF 60 µg
Biological
Lead sponsor
Pfizer
Industry
Eligibility
2 Years to 17 Years
Enrollment
128 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2024
U.S. locations
17
States / cities
Birmingham, Alabama • Palo Alto, California • Rolling Hills Estates, California + 12 more
Conditions
Respiratory Syncytial Virus Infection
Interventions
Abrysvo, Beyfortus
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 45 Years · Female only
Enrollment
181 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2026
U.S. locations
8
States / cities
Atlanta, Georgia • Baltimore, Maryland • New York, New York + 5 more
Conditions
Respiratory Syncytial Virus (RSV)
Interventions
RSVpreF Vaccine
Biological
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
440 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
1
States / cities
Rochester, New York
Active, not recruiting Phase 3 Interventional Accepts healthy volunteers

Study to Evaluate the Efficacy, Immunogenicity, and Safety of RSVpreF in Adults.

NCT05035212
Conditions
Lower Respiratory Tract Illness
Interventions
RSVpreF, Placebo
Biological
Lead sponsor
Pfizer
Industry
Eligibility
60 Years and older
Enrollment
38,861 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2027
U.S. locations
176
States / cities
Birmingham, Alabama • Huntsville, Alabama • Glendale, Arizona + 119 more